Spencer Health Solutions, Inc., a leading pharma services and health technology firm, has successfully closed its Series D funding round, raising an initial $43 million. The company anticipates additional funding before the year concludes. This capital infusion will be instrumental in scaling the company’s growth in clinical trials, patient support services, and furthering partnerships with major pharmaceutical entities, clinical packagers, and specialty pharmacies.
Key Highlights
- Spencer Health Solutions raised an initial $43 million in its Series D funding round, with expectations of more funding by year-end.
- The funding will be utilized to convert debt to equity and to scale growth in clinical trials and patient support services.
- The company has built partnerships with several major pharmaceutical companies, global clinical packagers, and regional and national specialty pharmacies.
- Spencer Health Solutions’ spencer® medication dispensing technology has catered to over 5,800 patients across the US, Canada, and Europe.
Source: Business Wire
Notable Quotes
- “Our Series D will convert our debt to equity and bring in new capital to help us scale pharmaceutical company growth in clinical trials and patient support services from the home. This round of funding reflects our progress in building partnerships with several major pharmaceutical companies, global clinical packagers, and regional and national specialty pharmacies. It will also help support and scale several major chronic care provider contracts recently awarded in US, Canada and Europe. It is an exciting time at Spencer Health Solutions.” – Tom Rhoads, CEO of Spencer Health Solutions
SoH's Take
- Spencer Health Solutions’ successful Series D funding round underscores the growing demand and recognition for innovative health technology solutions in the pharmaceutical and care management sectors.
- The company’s strategic partnerships with major pharmaceutical entities and its expanding footprint across North America and Europe position it well for sustained growth. The focus on patient engagement and medication adherence, especially in the realm of clinical trials, indicates a forward-thinking approach that aligns with the evolving needs of the healthcare industry.
